Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis.
Gilead Sciences, Inc.has announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey...
An overview of asthma and COPD, including symptoms and diagnosis.
EMA has been advised by RepliGen of its decision to withdraw its application for SecreFlo (synthetic secretin human) as an...
Novartis announced that results of a global Phase III study (EVOLVE-1) showed that Afinitor (everolimus) did not extend overall survival...
The FDA approved the first generic version of Xeloda an oral chemotherapy pill used to treat cancer of the colon...